International Journal of Endocrinology / 2017 / Article / Tab 4

Clinical Study

The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation

Table 4

Results of multivariate logistic regression models for the regression of IMT of ≥0.10 mm from baseline at the end of the study.

FactorMean IMTRight max IMTLeft max IMT
Adjusted odds ratio (95% CI)P valueAdjusted odds ratio (95% CI)P valueAdjusted odds ratio (95% CI)P value

Age (1 year)1.01 (0.95–1.06)0.830.98 (0.94–1.02)0.371.01 (0.97–1.06)0.61
Gender (male/female)1.99 (0.83–4.79)0.120.67 (0.33–1.35)0.261.02 (0.49–2.14)0.95
Body mass index (1 kg/m2)1.07 (0.95–1.20)0.261.03 (0.94–1.13)0.561.00 (0.91–1.10)0.98
Estimated duration of diabetes (1 year)1.02 (0.97–1.07)0.420.99 (0.95–1.03)0.651.02 (0.98–1.07)0.26
Smoking (yes/no)1.93 (0.67–5.52)0.220.72 (0.30–1.74)0.471.83 (0.77–4.35)0.17
HbA1c (1 mmol/l)1.04 (0.69–1.56)0.871.07 (0.76–1.51)0.681.00 (0.70–1.44)0.99
Systolic BP (1 mmHg)0.99 (0.96–1.02)0.401.03 (1.01–1.06)0.0120.97 (0.94–0.99)0.02
Total cholesterol (1 mmol/l)0.64 (0.35–1.18)0.161.11 (0.69–1.79)0.681.19 (0.72–1.95)0.49
HDL cholesterol (1 mmol/l)0.44 (0.11–1.78)0.251.19 (0.38–3.75)0.760.69 (0.22–2.15)0.52
Triglyceride (1 mmol/l)0.92 (0.58–1.44)0.710.87 (0.59–1.29)0.51.00 (0.72–1.38)1.00
eGFR (1 ml/min/1.73 m2)1.01 (0.99–1.03)0.271.00 (0.98–1.01)0.741.01 (0.99–1.03)0.22
Baseline cIMT (0.01 mm)1.05 (1.03–1.08)<0.0011.02 (1.01–1.03)<0.0011.02 (1.01–1.03)<0.001
Treatment group (sitagliptin
treatment/conventional treatment)
3.58 (1.60–7.99)0.0022.02 (1.07–3.84)0.0312.38 (1.23–4.58)0.01
ACE/ARB (yes/no)1.10 (0.50–2.45)0.810.86 (0.45–1.68)0.671.31 (0.66–2.63)0.44
Statins (yes/no)0.76 (0.33–1.74)0.511.27 (0.64–2.49)0.490.88 (0.44–1.76)0.72
Antiplatelets (yes/no)0.34 (0.12–0.96)0.040.79 (0.35–1.79)0.570.40 (0.17–0.97)0.042
OHA (yes/no)0.55 (0.26–1.18)0.120.83 (0.43–1.58)0.560.53 (0.27–1.04)0.064
Changes in systolic BP at 104 weeks
from baseline (1 mmHg)
1.00 (0.98–1.03)0.941.02 (1.00–1.04)0.0790.99 (0.97–1.01)0.45
Changes in HbA1c at 104 weeks from
baseline (1 mmol/l)
1.25 (0.84–1.87)0.271.13 (0.80–1.60)0.490.91 (0.64–1.29)0.59
Changes in total cholesterol at 104 weeks
from baseline (1 mmol/l)
0.97 (0.94–1.00)0.0510.99 (0.97–1.02)0.450.99 (0.96–1.01)0.30
Changes in HDL cholesterol at 104 weeks
from baseline (1 mmol/l)
1.00 (0.97–1.02)0.761.01 (0.99–1.03)0.331.01 (0.98–1.03)0.59
Changes in triglyceride at 104 weeks from baseline (1 mmol/l)1.00 (0.99–1.00)0.391.00 (1.00–1.01)0.221.00 (0.99–1.01)0.85

Multivariate logistic regression models were used to identify the determination of the regression of IMT of ≥0.10 mm from baseline at the end of the study.
ACE/ARB, angiotensin-converting enzyme/angiotensin II receptor blocker; BP, blood pressure; IMT, intima-media thickness; eGFR, glomerular filtration rate; OHA, oral hypoglycemic agents.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.